Wellmarker Bio said it has introduced Medidata’s Rave Study Feasibility, a test institution assessment solution, and Rave EDC, an integrated data solution, for the phase 1 clinical trial of its colorectal cancer treatment candidate, WM-S1.

Wellmarker Bio is a spin-off of Asan Medical Center founded in December 2016, which has since been developing customized therapies for cancer patients based on the predictive biomarker. Medidata is a provider of a cloud-based solution for bioscience clinical trials.

Wellmarker Bio’s WM-S1 is a low-molecular drug for colorectal cancer patients who have resistance against the standard treatment, Erbitux.

Wellmarker Bio has introduced Rave Study Feasibility to select clinical trial institutions and optimize data management and plans to use Rave EDC for data collection and management. The company plans to conduct trials in Korea, Australia, and the U.S. It has successfully selected an Australian clinical trial agency through Rave Steady Feasibility.

"Medidata's solution, which can predict the patient recruitment rate of each institution amid the Covid-19 pandemic, allowed the fastest and most efficient initial clinical trials," Wellmarker Bio CEO Jin Dong-hoon said.

Medidata Vice President Journey Hong said, "We will help Wellmarker Bio identify clinical institutions with the highest registration rate and propel the development of innovative new drugs through our Rave Study Feasibility and Rave EDC, based on the largest clinical repository of 22,000 healthcare institutions in 94 countries."

Hong explained that accurate analysis and choosing clinical trial centers and collecting and managing data by global standards is the first step to improving clinical studies' efficiency and success.